id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-1888-0006,FDA,FDA-2016-E-1888,"Determination of Regulatory Review Period for Purposes of Patent
Extension; DARZALEX",Notice,Determinations,2018-02-20T05:00:00Z,2018,2,2018-02-20T05:00:00Z,2018-08-21T03:59:59Z,2018-02-20T15:02:40Z,2018-03342,0,0,0900006482f45478